seri
etacryn
acid
deriv
synthes
screen
vitro
activ
plasmodium
falciparum
well
activ
recombinantli
express
two
activ
compound
seri
display
ic
valu
plasmodia
malaria
still
major
caus
global
human
morbid
mortal
plasmodium
falciparum
deadliest
among
four
plasmodium
speci
infect
human
annual
million
clinic
malaria
episod
occur
caus
million
death
year
increas
spread
p
falciparum
due
inadequ
vector
control
increas
drug
resist
lack
effect
vaccin
strengthen
need
develop
novel
drug
treatment
malaria
new
therapeut
strategi
therefor
urgent
need
cystein
proteas
p
falciparum
repres
attract
antiplasmodi
drug
target
due
essenti
function
parasit
erythrocyt
cycl
among
locat
acid
food
vacuol
parasit
play
pivot
role
hemoglobin
hydrolysi
may
also
particip
erythrocyt
ruptur
disrupt
hemoglobin
degrad
pathway
lethal
parasit
develop
compound
target
therefor
current
focu
research
recent
studi
shown
individu
cystein
proteas
inhibitor
significantli
reduc
microgametogenesi
p
falciparum
point
potenti
role
inhibitor
transmiss
block
strategi
far
sever
peptid
peptidomimet
well
nonpeptid
cystein
proteas
inhibitor
synthes
test
malaria
parasit
present
work
set
nonpeptid
cystein
proteas
inhibitor
deriv
loop
diuret
etacryn
acid
lead
compound
evalu
potenc
inhibit
recombinantli
express
furthermor
activ
chloroquinesensit
p
falciparum
strain
chloroquineresist
strain
investig
sever
compound
initi
test
papain
prototyp
cystein
proteas
famili
sar
coronaviru
main
proteas
pro
describ
elsewher
previou
studi
compound
possess
activ
doubl
bond
reveal
coval
revers
bind
cystein
residu
respect
proteas
addit
structur
modif
implement
previou
work
name
within
compound
includ
fluorosubstitut
compound
sever
analogu
without
activ
doubl
bond
well
deriv
polar
side
chain
final
biotinlabel
inhibitor
summari
structur
etacryn
acid
modifi
follow
scheme
substitut
pattern
aromat
ring
b
ester
amid
c
orthoposit
doubl
bond
contain
side
chain
cpd
remov
doubl
bond
inhibitor
synthes
accord
previous
describ
pathway
summar
scheme
halogen
substitut
anisol
subject
friedelcraft
acyl
yield
correspond
phenol
keton
alkyl
phenol
hydroxyl
function
yield
amid
ester
introduct
doubl
bond
perform
either
mannich
reaction
tmdm
aldol
condens
formaldehyd
latter
yield
free
acid
due
concurr
hydrolysi
ester
function
free
acid
coupl
variou
amid
give
amid
amid
without
activ
doubl
bond
also
synthes
standard
amid
coupl
method
brch
co
r
k
co
ki
recombin
produc
previous
describ
inhibitori
activ
recombin
evalu
fluorometr
micropl
assay
use
substrat
cbzpheargamc
cbzleuargamc
amc
cystein
proteas
inhibitor
use
posit
control
solvent
dmso
use
neg
control
compound
test
vitro
cqsensit
p
falciparum
strain
cqresist
p
falciparum
strain
ic
valu
shown
tabl
vitro
data
etacryn
acid
deriv
compar
well
known
drug
chloroquin
addit
cytotox
inhibitor
studi
human
kidney
epithelium
celllin
describ
previous
result
ic
valu
inspect
data
tabl
allow
follow
conclus
drawn
gener
etacryn
acid
deriv
weak
moder
inhibitor
falcipain
p
falciparum
nevertheless
structureact
relationship
found
ethyl
ester
deriv
potent
etacryn
acid
accord
result
papain
sarscov
pro
dichlorosubstitut
compound
eg
better
inhibitor
monochloro
eg
fluorosubstitut
compound
one
except
name
inhibitor
compar
system
appear
favour
activ
falcipain
compar
analog
dichlorocompound
compound
short
volumin
moieti
tertbutyl
moieti
compound
seem
advantag
combin
fluorosubstitut
arom
case
activ
doubl
bond
appar
essenti
inhibit
nearli
etacryn
acid
amid
show
better
inhibit
properti
free
acid
longer
acid
sidechain
significantli
enhanc
activ
compar
make
activ
inhibitor
falcipain
p
falciparum
within
seri
howev
insert
addit
acid
group
eg
diminish
inhibit
activ
cytotoxicityantiplasmodi
ratio
activ
compound
indic
select
parasit
data
target
enzym
parasit
correl
case
eg
question
aris
whether
addit
target
order
allow
affin
bind
studi
biotinyl
dichlorosubstitut
etacryn
acid
amid
includ
synthes
accord
method
recent
describ
scheme
notabl
compound
emerg
potent
inhibitor
falcipain
p
falciparum
within
seri
summari
paper
describ
comprehens
screen
nonpeptid
michael
acceptor
use
etacryn
acid
lead
structur
best
inhibit
recombinantli
synthes
reveal
compound
moreov
etacryn
acid
amid
well
compound
display
modest
antiplasmodi
activ
vitro
ic
valu
respect
rang
standard
cystein
proteas
inhibitor
addit
high
ic
valu
compound
obtain
cytotox
assay
use
human
kidney
epithelium
celllin
indic
select
parasit
result
provid
basic
inform
develop
nonpeptid
irrevers
cystein
proteas
inhibitor
etacryn
acid
amid
lead
compound
addit
good
inhibitori
properti
allow
affin
bind
studi
melt
point
determin
open
capillari
melt
point
apparatu
model
switzerland
nmr
spectra
record
avanc
mhz
spectromet
bruker
biospin
gmbh
germani
solvent
cdcl
unless
otherwis
note
hnmr
mhz
cnmr
mhz
optic
rotat
valu
determin
perkinelm
polarimet
esi
mass
spectra
record
agil
ion
trap
equip
agil
hplc
system
hydrostat
column
chromatographi
perform
silica
gel
mm
solvent
purifi
dri
prior
use
accord
standard
literatur
procedur
chloroquin
dmso
dimethyl
sulfoxid
obtain
sigmaaldrich
deisenhofen
germani
alamar
blue
purchas
trinova
biochem
giessen
germani
dmem
dulbecco
modifi
eagl
medium
high
glucos
deliv
gibcosigmaaldrich
deisenhofen
germani
hygromycin
obtain
merck
darmstadt
germani
synthes
compound
describ
method
introduct
doubl
bond
substanc
equiv
tmdm
n
n
n
ntetramethyldiaminomethan
equiv
acet
anhydrid
equiv
ad
slowli
mixtur
heat
reflux
reaction
follow
hnmr
spectroscopi
complet
reaction
mixtur
cool
room
temperatur
satur
k
co
solut
ad
ga
evolut
stop
product
extract
et
wash
water
brine
dri
na
solvent
remov
vacuo
product
purifi
column
chromatographi
method
b
synthes
bromoacetamid
bromoacetyl
bromid
equiv
absolut
ch
cl
cool
amin
equiv
triethylamin
equiv
absolut
ch
cl
ad
dropwis
addit
reaction
mixtur
warm
room
temperatur
stir
h
solvent
remov
vacuo
product
dissolv
aceton
filter
bromoacetamid
use
directli
without
purif
method
c
coupl
bromoacetamid
bromoacet
acid
ester
equiv
k
co
equiv
ki
equiv
reflux
dri
aceton
h
bromoacetamid
method
b
bromoacet
acid
ester
equiv
ad
mixtur
heat
reflux
h
mixtur
cool
room
temperatur
filter
solvent
remov
vacuo
product
dissolv
et
wash
brine
koh
solut
water
dri
na
solvent
remov
vacuo
product
purifi
column
chromatographi
g
mmol
butyr
acid
chlorid
g
mmol
dissolv
n
atmospher
absolut
ch
cl
ml
mixtur
cool
alcl
g
mmol
ad
within
minut
mixtur
stir
h
addit
amount
alcl
g
mmol
ad
mixtur
heat
reflux
h
mixtur
pour
ice
acidifi
concentr
hcl
ph
tartar
acid
ad
complex
aluminum
solut
clear
solut
extract
et
organ
layer
wash
koh
solut
brine
organ
layer
dri
na
solvent
remov
vacuo
yield
acet
g
mmol
bromoacet
acid
ethyl
ester
g
mmol
k
co
g
mmol
ki
mg
mmol
reflux
dri
aceton
h
reaction
mixtur
cool
room
temperatur
filter
solvent
remov
vacuo
product
extract
butanoyl
phenoxi
acet
acid
mg
mmol
nhydroxysuccinimid
mg
mmol
dissolv
n
atmospher
absolut
ch
cl
ml
dicyclohexylcarbodiimid
dcc
mg
mmol
ad
small
portion
mixtur
stir
overnight
mixtur
filter
flask
tertbutylamin
mg
mmol
ch
cl
ml
stir
h
room
temperatur
filter
reaction
mixtur
wash
brine
koh
solut
dri
na
solvent
remov
vacuo
product
purifi
column
chromatographi
r
f
cyclohexaneethyl
acet
yield
mg
mmol
white
solid
mp
cyclohexaneethyl
acet
loopesim
calcd
c
compound
synthes
accord
compound
synthes
accord
start
etacryn
acid
mg
mmol
nhydroxysuccinimid
mg
mmol
dcc
mg
mmol
dichloromethan
ml
solvent
remov
residu
taken
thf
solut
ad
solut
acid
mg
mmol
koh
mg
mmol
water
ml
day
stir
room
temperatur
mixtur
acidifi
conc
hcl
extract
dichloromethan
remov
organ
solvent
crude
product
yield
yellow
oil
purifi
column
chromatographi
meohchcl
product
colourless
oil
solidifi
white
solid
yield
mg
mmol
hnmr
meoh
j
hz
ch
ch
ch
ch
coupl
bocdiaminohexan
dbiotin
bocdiaminohexan
mg
mmol
dbiotin
mg
mmol
suspend
absolut
dmf
ml
cool
dppa
mg
mmol
triethylamin
mg
mmol
ad
mixtur
stir
day
dichloromethan
ml
ad
organ
phase
wash
twice
citric
acid
upon
addit
water
organ
phase
amid
precipit
white
solid
filter
compound
synthes
accord
start
acid
mg
mmol
nhydroxysuccinimid
mg
mmol
dcc
mg
mmol
tbutylamin
mg
mmol
dichloromethan
ml
compound
synthes
accord
start
acid
mg
mmol
nhydroxysuccinimid
mg
mmol
dcc
mg
mmol
nbutylamin
mg
mmol
dichloromethan
ml
recombinantli
express
e
coli
refold
activ
enzym
previous
describ
ic
valu
inhibit
determin
describ
previous
use
fluorogen
substrat
cbzpheargamc
cbzleuargamc
respect
amc
methylcoumarin
posit
control
wellknown
cystein
proteas
inhibitor
neg
control
solvent
dmso
use
dosedepend
effect
compound
parasit
develop
p
falciparum
strain
quantifi
flow
cytometri
accord
previous
publish
method
first
screen
inhibitor
concentr
mm
perform
percentag
activ
infect
red
blood
cell
rbc
rel
neg
control
determin
compound
show
concentr
depend
inhibit
assay
select
determin
ic
valu
tabl
chloroquin
use
posit
control
solvent
dmso
use
neg
control
select
compound
assay
p
falciparum
strain
perform
use
fluorometr
assay
microcultur
tetrazolium
test
measur
parasit
lactat
dehydrogenas
activ
parasit
cultiv
vitro
describ
previous
compound
screen
concentr
nm
synchron
ring
stage
plate
plate
parasitemia
presenc
compound
dissolv
dmso
incub
parasit
dmso
alon
concentr
vv
use
neg
control
ic
valu
calcul
nonlinear
regress
analys
use
program
gaphpad
prism
grafit
human
kidney
epitheliumcel
line
cultur
dmem
medium
supplement
fetal
bovin
serum
lglutamin
mm
humidifi
atmospher
contain
co
experiment
procedur
cell
detach
flask
rubber
policeman
wash
twice
pb
phosphatebuff
salin
contain
ml
trypsinedta
x
suspend
x
cell
ml
complet
medium
inhibitor
assay
carri
describ
elsewher
except
cell
concentr
use
studi
x
ml
well
